动脉粥样硬化症治疗性疫苗的研究进展

动脉粥样硬化是引起心血管疾病的病理学基础，临床上已有多种药物治疗的方法。基因治疗与疫苗治疗是最新发展的治疗方法，目前相关研究十分活跃，CETi-1疫苗是美国Avant公司研究开发的抗动脉粥样硬化的肽疫苗，由破伤风毒素的Th细胞表位14个氨基酸连接人胆固醇酯转移蛋白B细胞表位的16个氨基酸，并在N端加1个半胱氨酸构建而成。它注入人体后可以引起人体免疫反应，产生能结合CETP的抗体，抑制高密度脂蛋白向低密度脂蛋白的转化，因而具有抗动脉粥样硬化的生物学效应。

Advances in therapeutic vaccine of antiatherogeny

Atherosclerosis is one of the primary pathology basis of the cardiovascular disease,and many drugs have been found to treat it.The research about the latest therapies like gene therapy and vaccine therapy is very active.CETi-1vaccine is peptide vaccine which American Avant corporation developed to prevent atherosclerosis.The vac-cine,produced by peptide synthesis,is a31amino-acid synthetic chimeric peptide that contains an N-terminal cys-teine,a B-cell epitope,which comprises residues461-476of human CETP,and a T-cell epitope,which comprises residues830-843of the tetanus toxin.Avant's novel vaccine works by eliciting antibodies that block the activity of cholesteryl ester transfer protein (CETP),a molecular that mediates the movement of cholesterol from high density lipoproteins(HDLs)to low density lipoproteins(LDLs).By blocking CETP activity,levels of HDLs can be increased.Increasing HDL levels is a significant step towards preventing atherosclerosis.